Milestone Pharmaceuticals Inc. Insider Trading

MIST

Last 12 months

Insiders sold $1.18M and bought nothing on the open market.

15% of the selling was scheduled in advance under 10b5-1 plans. President and CEO Joseph Oliveto sold 375K on Jan 26, 26% of their stake, outside a plan. The last open-market buy by an executive or director was in Dec 2022.

Net open-market

−$1.18M

0 buys · 7 sales

Under a 10b5-1 plan

15%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Dec 2022

Dec 5, 2022

Get an email when MIST's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 16	Joseph Oliveto President and CEO	Sold10b5-1 plan	36,500	$2.26	82K	7.6%	Form 4
Dec 15, 2025 – Jan 26	Jeffrey Edward Nelson Chief Operating Officer	SoldNo plan 2 parts	70,252	$2.25 average	158K	58%	Form 4
Dec 15, 2025 – Jan 26	David Bharucha Chief Medical Officer	SoldNo plan 2 parts	70,252	$2.25 average	158K	38%	Form 4
Dec 15, 2025 – Jan 26	Amit Hasija CFO & EVP of Corp. Development	SoldNo plan 2 parts	70,252	$2.25 average	158K	41%	Form 4
Dec 15, 2025 – Jan 26	Lorenz Muller Chief Commercial Officer	SoldNo plan 2 parts	64,746	$2.25 average	146K	24%	Form 4
Dec 15, 2025 – Jan 26	Joseph Oliveto President and CEO	SoldNo plan 2 parts	167,577	$2.24 average	375K	26%	Form 4
Jan 7 – 8	Joseph Oliveto President and CEO	Sold10b5-1 plan 2 parts	43,500	$2.25 average	98K	13%	Form 4

Apr 1610b5-1 plan
Joseph Oliveto
President and CEO · sold 36,500 at $2.26
82K
7.6% of stake
Dec 15, 2025 – Jan 26No plan
Jeffrey Edward Nelson
Chief Operating Officer · sold 70,252 at avg $2.25
158K
58% of stake
Dec 15, 2025 – Jan 26No plan
David Bharucha
Chief Medical Officer · sold 70,252 at avg $2.25
158K
38% of stake
Dec 15, 2025 – Jan 26No plan
Amit Hasija
CFO & EVP of Corp. Development · sold 70,252 at avg $2.25
158K
41% of stake
Dec 15, 2025 – Jan 26No plan
Lorenz Muller
Chief Commercial Officer · sold 64,746 at avg $2.25
146K
24% of stake
Dec 15, 2025 – Jan 26No plan
Joseph Oliveto
President and CEO · sold 167,577 at avg $2.24
375K
26% of stake
Jan 7 – 810b5-1 plan
Joseph Oliveto
President and CEO · sold 43,500 at avg $2.25
98K
13% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MIST, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MIST

CompareIntrinsic value

BSPKBespoke Extracts Inc.

$0.00+0.00%30

LEXXLexaria Bioscience Corp.

$4.07+0.99%10

GANXGain Therapeutics Inc.

$1.11-3.48%25

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

XENEXenon Pharmaceuticals Inc.

$39.19+2.50%10

ONCBeOne Medicines Ltd.

$377.78+6.42%65

ASMBAssembly Biosciences Inc.

$19.87-0.25%19

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

Held by ETFs

MIST is in 2 US ETFs. The largest of them, with MIST's weight in each:

Spot a number that looks wrong? Check it in MIST's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MIST

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.